LY3022855: Clinical Trials

4 trials of LY3022855, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 4
Phase 21Completed 1

Follow LY3022855: new trials by email Literature Review of LY3022855 trials Research Report on LY3022855

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
LY3022855, Vemurafenib, Cobimetinib - Melanoma
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute52017-06-062024-07-17
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
LY3022855, Durvalumab, Tremelimumab - Solid Tumor
Phase 1CompletedEli Lilly and Company722016-06-162023-10-16
A Study of LY3022855 In Participants With Breast or Prostate Cancer
LY3022855 - Neoplasms, Neoplasm Metastasis
Phase 1CompletedEli Lilly and Company342015-05-012024-10-28
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors
IMC-CS4 - Neoplasms
Phase 1CompletedEli Lilly and Company522011-06-152024-09-19

Conditions studied

Neoplasms (2)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)

Sponsors

Eli Lilly and Company (3)  ·  Dana-Farber Cancer Institute (1)

Countries

United States (4)  ·  Belgium (1)  ·  Czechia (1)  ·  Israel (1)

Top investigators

Elizabeth Buchbinder, MD (1)

Results publications

PMID 32847933, PMID 33624233, PMID 33852104

NIH funding

2016 (1)